Updated on Nov 19, 2025 | Artificial Intelligence, Community, Engagement, Featured
Alexander Charney, MD, PhD
An essential part of achieving health equity is the fair collection of genomic data, ensuring that informed health care decisions can reflect the unique, diverse genomes of all cultures. Currently, there is a lack of diversity in genomic research data. This limits what we can uncover about health and potential treatments for our global population.
Expanding diversity among participants in genomic research can bridge these gaps, advancing our understanding of human genetics for all communities. One ambitious initiative that strives to diversify this data is the Mount Sinai Million Health Discoveries Program.
Mount Sinai Health System’s Health Equity Data Assessment (HEDA) team met with leaders of the program who expressed their challenge with identifying the ethnic identities of Mount Sinai patients participating in the program. HEDA was quickly able to assist in rectifying the data issue, which resulted in increasing the ethnic identities from 0.5 percent to 66 percent.
This assistance will have a significant impact on the program objectives. A hypothesis was formulated in the Measures and Outcomes section of the HEDA Hub. The HEDA team will track progress towards the program’s goal of reaching a million patients.
The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai leads this project and aims to sequence the genomes of one million Mount Sinai patients over the next five years. It seeks to integrate health and research data to drive discoveries that directly benefit a diverse patient population.
Lea K. Davis, PhD
Mount Sinai Million is poised to serve as a model for embedding genetics into routine clinical care. By leveraging data from one of the world’s most diverse patient populations within a massive New York City health system, this program seeks to deepen our understanding of the connections between genetics and disease.
In a recent conversation with Alexander Charney, MD, PhD, Director, The Charles Bronfman Institute for Personalized Medicine, and Associate Professor, Genetics and Genomic Sciences, Psychiatry, Neuroscience, Neurosurgery, and Artificial Intelligence and Human Health, Icahn Mount Sinai; and Lea K. Davis, PhD, Scientific Director of the Mount Sinai Million Health Discoveries Program, The Charles Bronfman Institute for Personalized Medicine, and Associate Professor of Medicine (Data-Driven and Digital Medicine), Icahn Mount Sinai, we gained further insight into this initiative.
Dr. Charney explains: “Our goal is to develop personalized treatments tailored not only to the disease but to the individual’s genetic makeup, which we know varies significantly across populations.”
“Equity is a core value of the scientific vision for the Mount Sinai Million,” says Dr. Davis. “We are thrilled to connect the program with HEDA and are looking forward to supporting equity-focused research through the development of this incredible resource.”
Reflecting on the broader impact, Dr. Charney says the initiative “isn’t just about collecting data; it’s about improving lives.” He envisions a health care system where genetic insights enable clinicians to make more informed, individualized decisions.
“With this kind of data,” he says, “we’re not just diagnosing based on symptoms—we’re diagnosing based on a person’s unique genetic and biological profile, which could mean a huge leap in effectiveness.”
With this forward-thinking approach, Dr. Charney and the Mount Sinai team are working toward a future where each person’s treatment is precise, effective, and, above all, personalized.
To enroll as a participant or to learn more about the Mount Sinai Million Health Discoveries Program, visit mountsinaimillion.org.
Updated on Nov 19, 2025 | Artificial Intelligence, Featured, Mount Sinai Morningside
Javier Zulueta, MD
A new program at Mount Sinai Morningside represents a valuable tool to catch lung cancer—the cancer responsible for the most deaths in both men and women—at its earliest stages when it is most treatable.
Harnessing the power of leading-edge technology, the Incidental Lung Nodule Program employs artificial intelligence to sift through radiology reports ordered for patients for various conditions, looking for incidental lung nodules. These innocuous-seeming spots, often discovered during routine tests for unrelated issues, can be silent harbingers of a potentially life-threatening condition.
The program is marking its first anniversary. In just one year, it has identified more than 3,000 patients, including smokers, former smokers, and non-smokers, who may be at risk. Of these, more than 1,500 people are being actively monitored for any changes in their lung nodules, enabling early detection and intervention.
Early detection is critical, according to Javier Zulueta, MD, Chief of the Division of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai Morningside.
“Our goal is to engage physicians, smokers, former smokers, and the public in early detection,” he says. “Through screening programs like ours, we can catch cancers early and significantly improve health outcomes.”
The program operates automatically, with computed tomography (CT) scans ordered for various conditions systematically scrutinized by computerized algorithms. For example, patients who may undergo scans for other cancers, heart disease, or following surgeries may be candidates for this program. Upon detection of a lung nodule, a multidisciplinary team, including specialized pulmonologists, steps in. Patients are quickly contacted, and a comprehensive follow-up plan is set in motion, ensuring monitoring, timely diagnosis, and treatment.
“The Incidental Lung Nodule Program shows our commitment to medical excellence and our dedication to serving the West Harlem community, which has elevated rates of lung cancer,” says Dr. Zulueta. “We offer not just treatment but empowerment through knowledge and early detection.”
Mount Sinai Health System has been a pioneer in the effort to diagnose lung cancers. The International Early Lung Cancer Action Project, whose goal is to ensure smokers and former smokers receive low-dose CT, was started at The Mount Sinai Hospital and has expanded around the world. Likewise, the Incidental Lung Nodule Program will be expanding across the Mount Sinai Health System.
According to the American Cancer Society, lung cancer is the second most common cancer in both men and women, not including skin cancer. Prostate cancer is more common in men and breast cancer is more common among women. Lung cancer is the leading cause of cancer deaths, according to the society. Most people diagnosed with lung cancer are 65 or older.
Updated on Nov 19, 2025 | Artificial Intelligence, Featured, School
Rosalind J. Wright, MD, MPH
Building on its long history of groundbreaking science and advocacy in public health, and its research strengths in exposomics, genomic sciences, genetics, and big data analysis, the Icahn School of Medicine at Mount Sinai has established a Department of Public Health to address the urgent and mounting medical and environmental challenges of the 21st century.
Renowned physician and researcher Rosalind J. Wright, MD, MPH, was named Chair of the department and inaugural Dean for Public Health. Dr. Wright is Horace W. Goldsmith Professor and, most recently, the former Dean of Translational Biomedical Sciences at Icahn Mount Sinai. She is a founding Co-Director of the Institute for Climate Change, Environmental Health, and Exposomics, the nucleus of Icahn Mount Sinai’s work on studying environmental exposures and their effects on development, health, and disease across the life course.
Dr. Wright, who has authored or coauthored more than 350 peer-reviewed journal articles and delivered more than 150 regional, national, and international presentations, has long been committed to mentoring the next generation of public health scientists, having trained nearly 100 predoctoral and doctoral students and postdoctoral fellows over her career.
Bolstering these efforts is Icahn Mount Sinai’s extraordinary research capabilities, which include being ranked No. 4 among U.S. medical schools in National Institutes of Health (NIH) funding for Public Health, and No. 2 for Genetics (Blue Ridge Institute for Medical Research 2023 fiscal year), and No. 1 nationally in National Institutes of Environmental Health Sciences funding.
In the following Q&A, Dr. Wright discusses the transformative steps that will further strengthen Icahn Mount Sinai’s leadership in public health education, research, and practice.
Mount Sinai has been on the front lines of public health for decades. Why a Department of Public Health now?
We’re already widely recognized for our strengths in exposomics, genomic sciences, genetics, and big data analysis. And our public health research and advocacy work has frequently raised our national profile through studies, symposia, and testimony we’ve given before congressional committees looking into public health reform. By carefully assessing that repertoire of strengths—which often is the envy of others in the field—and bridging them, we can create a public health ecosystem that would allow our teams to cohesively share new knowledge, skills, and technology.
How, specifically, do you envision this?
Imagine if we could seamlessly marry the work of our environmental scientists in exposomics and genomics with the work of our computational and computer scientists. We could bring those data streams together even more than we are already doing and factor in our artificial intelligence and machine learning expertise to make sense of data patterns and profiles involving thousands of variables. The result would be revelations and gains in the field of public health not possible in the past.
How do you get there?
One of the ways we plan to set the stage for those breakthroughs is cross-training our students and workforce. Our goal is a transdisciplinary trained workforce so that MDs, PhDs, and other clinicians have the skills to understand climate science, for example, and to use data science methods, such as machine learning, to more precisely identify health-relevant environmental and genetic factors impacting all of our patients. Likewise, we want our data scientists to acquire the same basic skills in epidemiology and environmental health sciences to enable team science. Those ambitious goals will clearly require innovation and change around public health education at Mount Sinai.
We’ll be establishing doctoral programs in public health areas where our research and practice can lead the field, such as climate science and exposomics. But first, our plans are to expand our Master of Public Health programs to synergistically feed into planned doctoral programs. The public health programs were created in 2001 and are the oldest and largest graduate studies at Mount Sinai. We want our new department to be not just an academic home for investigators and public health practitioners, but an incubator for real curricula innovation.
We have what I see as a key advantage over other institutions in the field that will fortify our work: Mount Sinai Health System and Icahn Mount Sinai serve the greater New York City region, which includes East Harlem, an area of Manhattan that has one of the most diverse patient populations in the United States. It amounts to a laboratory rich in socioeconomic strata perfectly suited for research and clinical and public health practice. Just as importantly, we’ve advanced our science through programs like the BioMe®️ BioBank Program, with its tens of thousands of DNA samples driving genetic, genomic, and epidemiologic investigations, and through the Mount Sinai Million Health Discoveries Program, where we’ve woven genetics into real-world clinical care and have a goal to sequence 1 million Mount Sinai patients.
All of these approaches are essential if we are going to reinvent our response to the kinds of public health challenges we are seeing today—which are the same challenges we urgently need to address as a health system, too—climate change and environmental exposures of children within their communities, which we know can lead to asthma, obesity, learning disabilities, and much more. These will disproportionately impact communities that are already more burdened by these disorders. Nothing will focus us more as a department than gaining a more-informed understanding of the nature and impact of health-relevant environmental hazards that may contribute to health disparities in our communities.
You are building on a formidable legacy. What are the most impactful discoveries Mount Sinai researchers have made over the decades?
Uncovering the impact of asbestos on human health has been among the most consequential. Our work can be traced to Dr. Irving Selikoff, a pioneering researcher, who created in the 1960s the nation’s first hospital division of occupational medicine at Mount Sinai. His research on asbestos-related disease shaped public policy for working men and women around the world. It was also responsible for the landmark 1970 Occupational Safety and Health Act.
More recently, we’ve actively studied per- and polyfluoroalkyl substances (PFAS), the class of synthetic chemicals ubiquitous in the environment and our bodies. Our investigators have developed novel metrics to gauge our cumulative exposure to PFAS and have shown how that exposure is linked to significant reductions in female fertility, as well as child health outcomes, such as asthma. We’re proud that our science is now informing regulatory change around PFAS, undertaken by the Environmental Protection Agency in 2023.
My own lab has done considerable work with air pollution exposure. We were among the first to link that exposure to asthma onset, as well as to cognitive dysfunction in children in early life, and to show that this starts in utero and weighs disproportionately on low income and ethnic minority populations. We were also among the first with research to show that psychological stress in pregnant women puts their babies at higher risk of developing conditions like asthma, given the impact of stress on the immune system.
What excites you most about your new role?
My passion throughout my career has been public health—from the time I started my fellowship in pulmonary medicine and felt the sudden need to get a Master in Public Health degree. I realized that this knowledge would help me to better understand the disparities I was seeing in my asthma patients—disparities I knew couldn’t be explained by heritability or genetics alone, which led me to studying broad environmental influences as well. In the same way, I feel I’m now in a position to do something really unique as the new Dean for Public Health—to translate the scientific capabilities that we can collectively bring together to improve the health of our communities. And there’s no better place to accomplish that than at Mount Sinai.
Watch a video to learn more about the vision for Public Health at Icahn Mount Sinai.
